(ABM FN-Dow Jones) Kiadis Pharma has received permission from the American regulator FDA to have a study conducted by the University of Ohio with so-called natural-killer cells. The biopharmaceutical company announced this on Wednesday morning.
The university wants to conduct research into the treatment of patients with acute leukemia by means of natural killer cells, which have been developed with the FC21 mbIL21 platform from Kiadis.
In March 2020, Kiadis hopes to treat the first patients.
ABM Financial News; [email protected]; Editorial staff: +31 (0) 20 26 28 999.
Share this article via: